Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

XDx Launches AlloMap® Molecular Expression Testing in Germany

Published: Thursday, April 05, 2012
Last Updated: Thursday, April 05, 2012
Bookmark and Share
Non-invasive blood test helps physicians monitor risk of acute cellular rejection in stable heart transplant recipients.

XDx, Inc. announced the launch of AlloMap® Molecular Expression Testing in Germany. AlloMap is XDx’s easy and convenient, non-invasive blood test that aids physicians in determining a stable heart transplant patient’s risk of acute cellular rejection without requiring the use of endomyocardial biopsy. Heart transplant specialists initiated use of AlloMap in selected German hospitals in March 2012, and XDx expects to make AlloMap available to additional German, Swiss and Austrian transplant centers throughout the second quarter of this year in the first stage of a broader European launch.

In the United States, AlloMap is FDA-cleared and has been on the market since 2005. In 2010, a study called Invasive Monitoring Attenuation Through Gene Expression (IMAGE) demonstrated that AlloMap was non-inferior to biopsy with respect to clinical outcomes, including survival and absence of graft dysfunction. In addition, the study showed a reduction in the use of biopsies by 75% on average. Patients also gave a higher satisfaction rating to AlloMap than biopsy for the method used for detecting rejection. Based on these results, AlloMap testing is recommended in the practice guidelines of the International Society for Heart and Lung Transplantation (ISHLT).

In April 2011, AlloMap received a CE mark in the European Union under the In Vitro Diagnostics Directive. Findings from a European study (CARGO II) of AlloMap will be presented at the ISHLT’s 32nd Annual Meeting & Scientific Sessions being held April 18-21, 2012 in Prague, Czech Republic. CARGO II was designed to further validate results from the landmark multi-center, prospective, validation study known as the Cardiac Allograft Rejection Gene Expression Observational (CARGO) study completed by XDx in the US.

Pierre Cassigneul, President and CEO of XDx, said, “We are excited to initiate the European AlloMap launch in Germany, which represents the largest heart transplant market in the EU, which overall is similar in size to the US market. Closely following the launch in Germany, we will soon begin making AlloMap available in Switzerland and Austria. By next year, we anticipate expanding our reach to additional large European markets.”

Jörg Stypmann, M.D., PhD, transplant cardiologist in the Department of Cardiology and Angiology of the University Hospital Münster, Germany, commented, “Heart transplant recipients must be regularly monitored for acute cellular rejection, and currently in our institution they undergo up to 15 invasive, protocol biopsy procedures in their lifetime. There is a great clinical need to determine a patient’s individual risk of rejection in order to spare them so many uncomfortable procedures, which also involve moderate risk of adverse events. We think that AlloMap, a non-invasive test with its high negative predictive value, can provide a much-needed alternative strategy to monitor effectiveness of immunosuppressive therapy during the first year after heart transplantation and in the longer term. AlloMap also can potentially reduce the number of right ventricular biopsies in stable patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Newborn Screening Test Developed For Rare, Deadly Neurological Disorder
Scientists have developed a new dried blood spot screening test for Niemann-Pick type C, with goal to speed diagnosis and treatment.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!